Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 6/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25103265 | 0.89 | BACE1 (0.41) | BACE1PTPN11MEN1MAPTTSHR | |
| SCHEMBL25095851 | 0.88 | BACE1 (0.39) | BACE1PTPN11MEN1MAPTTSHR | |
| SCHEMBL30217674 | 0.88 | BACE1 (0.39) | BACE1PTPN11MEN1MAPTTSHR | |
| SCHEMBL25105367 | 0.87 | BACE1 (0.40) | BACE1PTPN11MEN1MAPTTSHR | |
| SCHEMBL25104512 | 0.87 | ADORA3 (0.39) | BACE1PTPN11MEN1MAPTTSHR | |
| SCHEMBL25104141 | 0.86 | IRAK4 (0.38) | MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25104401 | 0.86 | BACE1 (0.42) | BACE1PTPN11ADORA3ADORA2ANR1H2 | |
| Hydrochloric Acid SCHEMBL29267031 | 0.86 | IRAK4 (0.38) | — | |
| SCHEMBL29266929 | 0.85 | BACE1 (0.39) | BACE1PTPN11MEN1MAPTTSHR | |
| SCHEMBL31211351 | 0.84 | PDE7A (0.34) | MAPTSMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | BACE1 668/4885PTPN11 4588/4885MEN1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.